- Home
- HSIC vs ROIV Comparison
HSIC vs ROIV Comparison
Compare HSIC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- ROIV
- Stock Information
- Founded
- HSIC 1932
- ROIV 2014
- Country
- HSIC United States
- ROIV United Kingdom
- Employees
- HSIC N/A
- ROIV N/A
- Industry
- HSIC Medical Specialities
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- HSIC Health Care
- ROIV Health Care
- Exchange
- HSIC Nasdaq
- ROIV Nasdaq
- Market Cap
- HSIC 9.0B
- ROIV 7.8B
- IPO Year
- HSIC 1995
- ROIV N/A
- Fundamental
- Price
- HSIC $74.67
- ROIV $10.99
- Analyst Decision
- HSIC Buy
- ROIV Buy
- Analyst Count
- HSIC 10
- ROIV 4
- Target Price
- HSIC $79.30
- ROIV $17.50
- AVG Volume (30 Days)
- HSIC 1.5M
- ROIV 7.3M
- Earning Date
- HSIC 08-05-2025
- ROIV 08-07-2025
- Dividend Yield
- HSIC N/A
- ROIV N/A
- EPS Growth
- HSIC 8.11
- ROIV N/A
- EPS
- HSIC 3.21
- ROIV N/A
- Revenue
- HSIC $12,669,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- HSIC $4.28
- ROIV $2.64
- Revenue Next Year
- HSIC $3.57
- ROIV $378.09
- P/E Ratio
- HSIC $23.27
- ROIV N/A
- Revenue Growth
- HSIC 1.75
- ROIV N/A
- 52 Week Low
- HSIC $60.56
- ROIV $8.73
- 52 Week High
- HSIC $82.49
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- HSIC 68.83
- ROIV 44.75
- Support Level
- HSIC $72.21
- ROIV $10.83
- Resistance Level
- HSIC $75.34
- ROIV $11.82
- Average True Range (ATR)
- HSIC 1.30
- ROIV 0.32
- MACD
- HSIC 0.25
- ROIV -0.07
- Stochastic Oscillator
- HSIC 88.35
- ROIV 16.24
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.